Insights Into Renal Cell Carcinoma (RCC)

Perspectives on drivers in treatment decisions in the management of RCC

Great Plains/Central/Midwest – March 14, 2024
Purchase Report

Faculty Chair

Manojkumar Bupathi, MD

Rocky Mountain Cancer Centers, Littleton, CO, USA

Mid-Atlantic – April 24, 2024
Purchase Report

Faculty Chair

Yasser Ged, MBBS

Johns Hopkins Hospital, Baltimore, MD, USA

Northwest – June 20, 2024
Purchase Report

Faculty Chair

Manojkumar Bupathi, MD

Rocky Mountain Cancer Centers, Littleton, CO, USA

More Information

  • Virtual Series

More Information

  • Virtual series

More Information

  • Virtual series
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of RCC
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.